Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy

Transplant International

Volumn 17, Issue 4, 2004, Pages 215-220

  Dittrich, Elisabeth ^a   Schmaldienst, Sabine ^a   Soleiman, Afschin ^a   Hörl, Walter H ^a   Pohanka, Erich ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Calcineurin inhibitor; Glomerulonephritis; Rapamycin; Renal transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; GLOMERULONEPHRITIS; HUMAN; HUMAN TISSUE; IMMUNOADSORPTION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; REMISSION;

ADULT; CALCINEURIN; CREATINE; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 2942562298     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.tb00431.x     Document Type: Article

References (15)

1. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356:194.
2. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59:3.
3. Kreis H, Cisterne JM, Land W. Sirolimus in association with mycophenolate mofetil induction for prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252.
4. Oberbauer R, Kreis H, Johnson RW et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study Group. Transplantation 2003; 76:364.
5. Denton MD, Galvanek EG, Singh A, et al. Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy. Am J Transplant 2001; 1:288.
6. 6 Nowack R, Birck R, van der Woude FJ et al. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349:774.
7. Budde K, Fritsche L, Neumayer HH. Differing proteinuria control with cyclosporin and tacrolimus. Lancet 1997; 349:330.
8. Krämer BK, Schweda F. Differing proteinuria control with cyclosporin and tacrolimus. Lancet 1997; 349:953.
9. Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003; 18:1260.
10. Dominguez J, Mahalati K, Kiberd B, et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70:1244.
11. Hadaya K, Wissing M, Broders E, et al. Conversion to sirolimus after renal transplantation: High failure rate due to nephrotic proteinuria and other adverse events. J Am Soc Nephrol 2003; 14:185A.
12. Jim B, Doyle A, Bloom RD. Rapamycin is associated with worsening proteinuria in transplant patients with renal injury: a report of four cases. J Am Soc Nephrol 2003; 14:65A.
13. Daniel C, Ziswiler R, Frey B, et al. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 2000; 8:52.
14. 14 Day CJ, Cockwell P, Lipkin GW, et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17:2011.
15. Gescuk BD, Davis JC. Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 2002; 14:515.